Cue Biopharma, Inc. (CUE)

Market Cap	53.75M
Revenue (ttm)	8.29M
Net Income (ttm)	-38.90M
Shares Out	76.85M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229,430
Open	0.6900
Previous Close	0.6900
Day's Range	0.6801 - 0.7399
52-Week Range	0.5406 - 1.9890
Beta	1.55
Analysts	Strong Buy
Price Target	3.00 (+328.94%)
Earnings Date	Nov 12, 2025

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in p...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 2, 2018
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: CUE
• Website: https://www.cuebiopharma.com

Financial Performance

In 2024, Cue Biopharma's revenue was $9.29 million, an increase of 69.16% compared to the previous year's $5.49 million. Losses were -$40.67 million, -19.83% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CUE stock is "Strong Buy." The 12-month stock price target is $3.0, which is an increase of 328.94% from the latest price.

Price Target

$3.0

(328.94% upside)

Analyst Consensus: Strong Buy